Podium to Practice: Chicago 2025 – GU: CheckMate 214

Podium to Practice: Chicago 2025 – GU: CheckMate 214

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sebastien Hotte

Icon Chair Speaker

Speakers

Dr. Nimira Alimohamed

Dr. Maria Jiang

Studies / Trials Discussed

4505 – Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.

This program has been made possible through unrestricted support from Ipsen.

Studies/trials discussed:

4505 – Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.
Tagged